Furthermore, in view of the documented role of AQP1 in murine tumour angiogenesis [10, 12], it is envisaged that in metastatic CRC patients, AQP1 inhibitors may have a role combined with anti-vascular endothelial growth factor (VEGF) therapy, or as an alternative anti-angiogenesis therapy in cases that become resistant to anti-VEGF therapy. This evidence concerns the gene VEGFA and neoplasm.